Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

The following is a summary of “Metabolic syndrome and increased susceptibility to renal cell carcinoma – a meta-analysis,” ...

A study identified a link between sex hormones and renal cell carcinoma, suggesting potential new treatment strategies.

What Is Renal Cell Carcinoma? It's the most common type of kidney cancer. Although it’s a serious disease, finding and treating it early makes it more likely that you’ll be cured. No matter ...

US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...